This Article Full Text Full Text (PDF) Retraction (v40,p566) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, H. Articles by Raizada, M. K. Search for Related Content PubMed PubMed Citation Articles by Wang, H. Articles by Raizada, M. K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Genes and Gene Therapy High Blood Pressure Hazardous Substances DB PHENYLEPHRINE Related Collections ACE/Angiotension receptors Animal models of human disease Other hypertension Genomics Hypertension - basic studies Hypertrophy Gene therapy

(Hypertension. 2000;35:202.)
© 2000 American Heart Association, Inc.

Scientific Contributions

Angiotensin I–Converting Enzyme Antisense Gene Therapy Causes Permanent Antihypertensive Effects in the SHR

Hongwei Wang; Phyllis Y. Reaves; Monica L. Gardon; Kimberley Keene; Drew S. Goldberg; Craig H. Gelband; Michael J. Katovich; Mohan K. Raizada

From the Department of Physiology, College of Medicine (H.W., P.Y.R., M.L.G., K.K., D.S.G., C.H.G., M.K.R.), and Department of Pharmacodynamics (M.J.K.), College of Pharmacy, University of Florida, and the University of Florida Brain Institute, Gainesville, Fla.

Correspondence to Mohan K. Raizada, PhD, Professor of Physiology, Department of Physiology, College of Medicine, University of Florida, PO Box 100274, Gainesville, FL 32610-0274. E-mail mraizada{at}phys.med.ufl.edu

Abstract—The renin-angiotensin system plays a critical role in the control of blood pressure (BP), and its hyperactivity is associated with the development and maintenance of hypertension. Although traditional pharmacological therapies targeted toward the inhibition of the renin-angiotensin system are effective in the control of this disease, they pose significant limitations. We used an antisense gene delivery strategy to circumvent these limitations and established that a single intracardiac administration of angiotensin type 1 receptor antisense (AT₁R-AS) causes permanent prevention of hypertension in the spontaneously hypertensive rat (SHR), an animal model of primary human hypertension. Our objectives in this study were 2-fold: to determine (1) whether the targeting of angiotensin I–converting enzyme (ACE) mRNA by a similar antisense strategy would prevent the SHR from developing hypertension and (2) whether the antihypertensive phenotype is transmitted to the offspring from the antisense-treated parents. Administration of a retroviral vector containing ACE antisense (LNSV-ACE-AS) caused a modest yet significant attenuation of high BP (15±2 mm Hg) exclusively in the SHR. This was associated with a complete prevention of cardiac and renovascular pathophysiological alterations that are characteristic of hypertension. Like their parents, the F₁ generation offspring of the LNSV-ACE-AS–treated SHR expressed lower BP, decreased cardiac hypertrophy, and normalization of renal arterial excitation-coupling compared with offspring derived from the LNSV-ACE-tS (truncated sense)–treated SHR. In addition, the endothelial dysfunction commonly observed in the SHR renal arterioles was significantly prevented in both parents and offspring of the LNSV-ACE-AS–treated SHR. Polymerase chain reaction followed by Southern analysis revealed that the ACE-AS was integrated into the SHR genome and transmitted to the offspring. These observations suggest that transmission of ACE-AS by retroviral vector may be responsible for the transference of normotensive phenotypes in the SHR offspring.

Key Words: SHR • viral delivery • hypertension • cardiac hypertrophy • renovascular responsiveness

This article has been cited by other articles:

				L. Pinilla, J. M. Castellano, M. Romero, M. Tena-Sempere, F. Gaytan, and E. Aguilar Delayed Puberty in Spontaneously Hypertensive Rats Involves a Primary Ovarian Failure Independent of the Hypothalamic KiSS-1/GPR54/GnRH System Endocrinology, June 1, 2009; 150(6): 2889 - 2897. [Abstract] [Full Text] [PDF]

				H. E. De Wardener The Hypothalamus and Hypertension Physiol Rev, October 1, 2001; 81(4): 1599 - 1658. [Abstract] [Full Text] [PDF]

				H. NAKAYA, H. SASAMURA, M. HAYASHI, and T. SARUTA Temporary Treatment of Prepubescent Rats with Angiotensin Inhibitors Suppresses the Development of Hypertensive Nephrosclerosis J. Am. Soc. Nephrol., April 1, 2001; 12(4): 659 - 666. [Abstract] [Full Text] [PDF]

				S. I. Garcia, A. L. Alvarez, P. I. Porto, V. M. Garfunkel, S. Finkielman, and C. J. Pirola Antisense Inhibition of Thyrotropin-Releasing Hormone Reduces Arterial Blood Pressure in Spontaneously Hypertensive Rats Hypertension, February 1, 2001; 37(2): 365 - 370. [Abstract] [Full Text] [PDF]

				M. Gardon, M. K Raizada, M. J Katovich, K. H Berecek, and C. H Gelband Gene therapy for hypertension and restenosis Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 211 - 216. [PDF]